Moran Wealth Management LLC Has $29.52 Million Position in Zoetis Inc. $ZTS

Posted by on Aug 16th, 2026

Moran Wealth Management LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 66.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 410,762 shares of the company’s stock after acquiring an additional 163,458 shares during the period. Zoetis accounts for 0.8% of Moran Wealth Management LLC’s holdings, making the stock its 20th biggest position. Moran Wealth Management LLC’s holdings in Zoetis were worth $29,517,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of ZTS. Brighton Jones LLC boosted its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC increased its position in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co lifted its holdings in shares of Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after buying an additional 506 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS opened at $73.64 on Friday. The company has a market cap of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.74. The stock has a 50-day moving average of $76.30 and a 200-day moving average of $99.01. Zoetis Inc. has a 52-week low of $71.45 and a 52-week high of $160.48. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the business earned $1.76 EPS. The firm’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 34.93%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. TD Cowen lowered their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Stifel Nicolaus cut their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Finally, Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $109.62.

Read Our Latest Analysis on ZTS

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.